Pro Research: Wall Street dives into CRISPR Therapeutics' gene editing future
Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This New Year, enjoy up to 50% off on a subscription to InvestingPro. In addition, take an extra 10% off a 2-year InvestingPro+ subscription with the code SFY24 or claim an extra 10% off a 1-year InvestingPro+ subscription with the code SFY241. To ensure ongoing access to valuable content like this, step up your investment game with InvestingPro.
The biotechnology sector is witnessing a paradigm shift as gene editing emerges as a transformative force in medicine. CRISPR Therapeutics AG (NASDAQ:CRSP), a frontrunner in this revolution, has recently garnered significant attention from Wall Street analysts. The company's proprietary CRISPR/Cas9 platform has shown promise in developing gene-based therapies for serious diseases, including sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
CRISPR Therapeutics has made headlines with the UK approval of its therapy CASGEVY for SCD/TDT patients, marking a significant milestone not only for the company but for the gene editing domain at large. The anticipated FDA approval in the US by early December 2023, with a high probability of 85%, could drive the stock's upside by 15-25%. However, analysts note that revenue generation from CASGEVY will take time, with a profitable turn expected around 2028 based on physician surveys.
The company's pipeline boasts promising therapies like CTX310 and CTX320 for cardiovascular diseases, with clinical trials expected to start in the first half of
Read more on investing.com
